Alitretinoin for the treatment of severe chronic hand eczema

Eczema (chronic) - alitretinoin: review decision - October 2012 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 45 KB)

Eczema (chronic) - alitretinoin: review proposal - August 2012 information

Appendix A: provisional matrix of stakeholders (PDF 52 KB)

Appendix B: Proposal paper presented to the institute's Guidance Executive (PDF 307 KB)

Eczema (chronic) - alitretinoin: final appraisal determination information

Eczema (chronic) - alitretinoin: final appraisal determination (PDF 130 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 158 KB)

Consultee and commentator comments on the ACD

Basilea Medical comments on the ACD (PDF 47 KB)

Basilea Medical comments on the evaluation report (PDF 22 KB)

British Association of Dermatologists (PDF 29 KB)

Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham (PDF 16 KB)

Department of Health (PDF 11 KB)

NHS Centre for Reviews & Dissemination and Centre for Health Economics - York (PDF 10 KB)

Royal College of Nursing (PDF 18 KB)

Royal College of Physicians (PDF 17 KB)

Skin Care Campaign and National Eczema Society (PDF 39 KB)

Comments from website consultation (PDF 164 KB)

Eczema (chronic) - alitretinoin: appraisal consultation

Eczema (chronic) - alitretinoin: appraisal consultation document information

Eczema (chronic) - alitretinoin: evaluation report

Eczema (chronic) - alitretinoin: pre-meeting briefing (PDF 104 KB)

Eczema (chronic) - alitretinoin: Evidence Review Group report (PDF 525 KB)

Eczema (chronic) - alitretinoin: non-manufacturer submissions

Eczema (chronic) - alitretinoin: Basilea Medical submission (PDF 1.52 MB)

Eczema (chronic) - alitretinoin: Royal College of Physicians (PDF 7.9 KB)

Eczema (chronic) - alitretinoin: British Contact Dermatitis Society (PDF 42 KB)

Eczema (chronic) - alitretinoin: manufacturer submission

Eczema (chronic) - alitretinoin: NICE clarification letter (PDF 1.37 MB)

Eczema (chronic) - alitretinoin: manufacturer response to clarification letter (PDF 1.37 MB)

Eczema (chronic) - alitretinoin: expert written personal statements

Eczema (chronic) - alitretinoin: Ormerod (PDF 14 KB)

Eczema (chronic) - alitretinoin: Langford (PDF 45 KB)

Eczema (chronic) - alitretinoin: Johnston (PDF 14 KB)

Eczema (chronic) - alitretinoin: final scope (PDF 28 KB)

Eczema (chronic) - alitretinoin: comments on the draft scope (PDF 59 KB)

Eczema (chronic) - alitretinoin: final matrix: of consultees and commentators (PDF 42 KB)

Eczema (chronic) - alitretinoin: draft scope (PDF 30 KB)

Eczema (chronic) - alitretinoin: comments on the draft matrix (PDF 26 KB)

Eczema (chronic)- alitretinoin: draft matrix of consultees and commentators (PDF 44 KB)